Virtual Library
Start Your Search
S. Sarihan
Author of
-
+
P2.04 - Poster Session with Presenters Present (ID 466)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.04-024 - Thymic Epithelial Tumors and Radiotherapy Results (ID 3702)
14:30 - 14:30 | Author(s): S. Sarihan
- Abstract
Background:
Thymic epithelial tumors (TET) treated with radiotherapy (RT) was evaluated for treatment outcomes and prognostic factors on survival.
Methods:
Between October 1995 and December 2013, 31 patients were treated. The median age was 44 (range: 19-83). There were 25 thymoma, 4 thymic carcinoma (TC) and 2 thymic neuroendocrin carcinoma (NEC). The incidence were found 13%, 39%, 39% and 9% for Masaoka stage I-II-III and IV, and 3%, 16%, 61%, 13% and 6%, for WHO type A-AB-B-C and NEC, respectively. Eighteen patients (58%) underwent R0 resection. Median RT dose was 5400 cGy (range: 1620-6596). Seven patients received a median of 6 cycles (range: 1-6) cisplatin-based adjuvant and 4 patients received weekly 60-70 mg/m2 paclitaxel or 2-3 cycles standart chemotherapy concurrently. According to prognostic risk stratification including Masaoka staging and WHO classification, cases were divided to good (n: 10), moderate (n: 9) and poor (n: 12) risk groups. Survival was calculated from diagnosis.
Results:
In January 2016, 22 cases lived with median 51.5 months (range: 2-170.5) follow-up. Recurrences were observed 9 (29%) of patients median 29.5 months (range: 6.5-105). Local control, mean overall (OS) and disease-free survival (DFS) rates for all patients, were 86%, 119 months (range: 94-144) and 116 months (range: 89-144), respectively. Local control were 100%, 89% and 75% for good, moderate and poor risk groups, respectively (p=0.08). There were a significant differences for Masaoka stage (I-II vs III-IV, p = 0.001, p <0.001), R0 resection (present vs absent, p = 0.06, p = 0.05), histology (thymoma vs TC, p = 0.02, p = 0.01) and prognostic risk groups (good vs moderate vs poor, p = 0.003, p = 0.004) in terms of OS and DFS, respectively.
Conclusion:
In our study, prognostic risk stratification was seen to be an important predictor for survival. The patients with TC was stage III-IV at diagnosis in moderate and poor risk groups indirectly and survival rates was found to be less than thymoma.
-
+
P2.05 - Poster Session with Presenters Present (ID 463)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Radiotherapy
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.05-006 - Radiotherapy as Definitive Treatment in Patients Aged 70 Years and Older with Non-Small Cell Lung Cancer (ID 3701)
14:30 - 14:30 | Author(s): S. Sarihan
- Abstract
Background:
The factors affecting survival were evaluated in patients aged ≥ 70 years with non-small cell lung cancer (NSCLC) treated with definitive radiotherapy (RT).
Methods:
Between January 1996 and April 2012, 52 patients were treated. The median age was 73 (range: 70-80), 73% and 75% of patients with stage III according to AJCC 2002 and 2010, respectively. Radiotherapy was performed median 6160 cGy (range: 3600-6660) and chemotherapy (CHE) were given 75% of the patients as neoadjuvant, concurrent or adjuvant. Statistical analysis were calculated with Kaplan-Meier and Cox regression methods.
Results:
Median follow-up was 12.5 months (range: 2.5-103). Median overall (OS), disease-free (DFS) and locoregional-progression-free (LRPFS) survival were 22 (95% CI 12-31), 18.5 (95% CI 7-29) and 25 months (95% CI 15-34), respectively. Two-year OS, DFS and LRPFS rates were 50%, 47% and 52%, respectively. Acute ≥ Grade 3 esophagitis and neutropenia were seen 6% and 10% of patients. Whereas the mortality associated with CHE were seen of 5 (10%) patients, RT-related death was not observed. In univariate analysis; AJCC 2002 stage I-II (72.5 vs 20 months, p = 0.05), RT dose ≥ 60 Gy (27.5 vs 12.5 months, p = 0.01), RT duration >49 days (31 vs 11 months, p <0.001) for OS and RT dose ≥ 60 Gy (25 vs 11 months, p= 0.02), RT duration >49 days (26.5 vs 10.5 months, p <0.001) neoadjuvant CHE ≤ 3 cycles (mean 58 vs 19 months, p = 0.03), complete response (72.5 vs 18.5 months, p = 0.03), ≥ 4 cycles of CHE (25 vs 11 months, p = 0.05) for DFS were significant. In multivariate analysis, RT duration > 49 days were found a positive impact on OS (HR: 3.235, 95% CI: 1:25 to 8:32 p = 0.01).
Conclusion:
Definitive and pallliative RT plays an important role in elderly lung cancer patients have multiple co-morbidities with limited treatment options. In our study, elderly patients with NCSLC can be given ≥ 60 Gy without complications and was seen positively impact on survival.
